Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gained

References

• Gerdtham U-G, Zethraeus N. Predicting survival in cost-effectiveness analyses based on clinical trials. Int J Technol Assess Health Care. 2003;19(3):507–512. doi: 10.1017/s0266462303000436.
   PubMed Web of Science ®Google Scholar
• Bullement A, Meng Y, Cooper M, et al. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available? J Med Econ. 2019;22(3):205–214. doi: 10.1080/13696998.2018.1547303.
   PubMed Web of Science ®Google Scholar
• Rohatgi A. WebPlotDigitizer; 2022. (version 4.6). Available at: https://automeris.io/WebPlotDigitizer. [Last accessed September, 2023]
   Google Scholar
• Guyot P, Ades A, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi: 10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016;122(13):2050–2056. doi: 10.1002/cncr.30026.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. (CLL11). Blood. 2009;114(16):3382–3391. doi: 10.1182/blood-2009-02-206185.
   PubMed Web of Science ®Google Scholar
• Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2010;19(1):43–55. doi: 10.1002/hec.1444.
   PubMed Web of Science ®Google Scholar
• Prasad V. Double-crossed: why crossover in clinical trials may be distorting medical science JNCCN. J Natl Compr Canc Netw. 2013;11(5):625–627. doi: 10.6004/jnccn.2013.0077.
   PubMed Web of Science ®Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021;3:100060. doi: 10.1016/j.lanepe.2021.100060.
   PubMedGoogle Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. (checkmate-057). N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927. doi: 10.1016/S1470-2045(16)30107-3.
   PubMed Web of Science ®Google Scholar
• Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–742. doi: 10.1016/S1470-2045(17)30312-1.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–1337. doi: 10.1016/S1470-2045(17)30578-8.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. (checkmate-141). N Engl J Med. 2016;375(19):1856–1867. doi: 10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Yen C-J, Kiyota N, Hanai N, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Head Neck. 2018;42(10):2852–2862. doi: 10.1016/j.oraloncology.2018.04.008.
   Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (CLL11). N Engl J Med. 2014;370(12):1101–1110. doi: 10.1056/NEJMoa1313984.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lungcancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Dimopoulos MA, Moreau P, et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk Lymphoma. 2017;58(10):2501–2504. doi: 10.1080/10428194.2017.1298755.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. (METEOR). Br J Cancer. 2018;118(9):1176–1178. doi: 10.1038/s41416-018-0061-6.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-Cell lung cancer. (keynote-024). N Engl J Med. 2016;375(19):1823–1833. doi: 10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. (EMILIA). N Engl J Med. 2012;367(19):1783–1791. doi: 10.1056/NEJMoa1209124.
   PubMed Web of Science ®Google Scholar